News

Arcutis Biotherapeutics, Inc. announced that Health Canada has accepted for review the New Drug Submission (NDS) for roflumilast cream 0.3% for the treatment of plaque psoriasis in…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company…
Read More...

WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology…
Read More...

ADC Therapeutics SA announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi) for the development and commercialization of ZYNLONTA for all…
Read More...

Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine,…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include…
Read More...

Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing…
Read More...

BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to…
Read More...

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, and TSB…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab),…
Read More...

Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center (“Moffitt”), a…
Read More...

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with…
Read More...

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed…
Read More...

CureVac N.V. announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to…
Read More...

Mogrify Limited and Astellas Pharma Inc. announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural…
Read More...

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the European Commission (EC)…
Read More...

ProteoNic BV and FyoniBio GmbH announced they have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for…
Read More...

Sanofi Global Health announces the launch of Impact, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the …
Read More...

Lonza announced plans to construct a large-scale commercial drug product fill and finish facility in Stein (CH). The investment will enable the company to provide customers with a…
Read More...

Vaxart, Inc. announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan plc under which hVIVO will conduct a characterization study and, if successful, develop a…
Read More...